CL2023003604A1 - Conjugados de neodegradadores - Google Patents

Conjugados de neodegradadores

Info

Publication number
CL2023003604A1
CL2023003604A1 CL2023003604A CL2023003604A CL2023003604A1 CL 2023003604 A1 CL2023003604 A1 CL 2023003604A1 CL 2023003604 A CL2023003604 A CL 2023003604A CL 2023003604 A CL2023003604 A CL 2023003604A CL 2023003604 A1 CL2023003604 A1 CL 2023003604A1
Authority
CL
Chile
Prior art keywords
neodegraders
conjugates
compositions
conjugated
cancer
Prior art date
Application number
CL2023003604A
Other languages
English (en)
Spanish (es)
Inventor
Fishkin Nathan
U Park Peter
Bai Chen
Original Assignee
Bristol Myers Squibb Co
Orum Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Orum Therapeutics Inc filed Critical Bristol Myers Squibb Co
Publication of CL2023003604A1 publication Critical patent/CL2023003604A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CL2023003604A 2021-06-03 2023-12-01 Conjugados de neodegradadores CL2023003604A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163202273P 2021-06-03 2021-06-03
US202163282585P 2021-11-23 2021-11-23

Publications (1)

Publication Number Publication Date
CL2023003604A1 true CL2023003604A1 (es) 2024-05-03

Family

ID=84323936

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023003604A CL2023003604A1 (es) 2021-06-03 2023-12-01 Conjugados de neodegradadores
CL2026000398A CL2026000398A1 (es) 2021-06-03 2026-02-10 Conjugados de neodegradadores.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2026000398A CL2026000398A1 (es) 2021-06-03 2026-02-10 Conjugados de neodegradadores.

Country Status (14)

Country Link
US (1) US20250090681A1 (https=)
EP (1) EP4346909A4 (https=)
JP (1) JP2024521921A (https=)
KR (1) KR20240040067A (https=)
CN (2) CN119499399A (https=)
AU (1) AU2022287316A1 (https=)
CA (1) CA3222182A1 (https=)
CL (2) CL2023003604A1 (https=)
CO (1) CO2023016711A2 (https=)
IL (1) IL308811A (https=)
MX (1) MX2023014284A (https=)
PE (1) PE20250115A1 (https=)
TW (1) TW202313124A (https=)
WO (1) WO2022254376A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058360A1 (en) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
EP4667463A1 (en) * 2023-02-15 2025-12-24 CSPC Megalith Biopharmaceutical Co., Ltd. Domide molecular glue derivative and use thereof
JP2026510495A (ja) * 2023-03-10 2026-04-07 リガケム バイオサイエンシズ， インク． ヒトｌ１ｃａｍに対する抗体を含む抗体－薬物コンジュゲートおよびその使用
WO2024222841A1 (zh) 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
WO2025168071A1 (zh) * 2024-02-08 2025-08-14 映恩生物制药（苏州）有限公司 一种含氮杂环化合物、其偶联物及其制备方法和用途
WO2025259615A1 (en) * 2024-06-11 2025-12-18 Triana Biomedicines, Inc. Modulators of cdk2 and uses thereof
WO2026007898A1 (zh) * 2024-07-01 2026-01-08 上海海雁医药科技有限公司 含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用
WO2026041050A1 (zh) * 2024-08-20 2026-02-26 海思科医药集团股份有限公司 一种配体-蛋白降解剂偶联物及其在医药上的应用
WO2026069278A1 (en) * 2024-09-30 2026-04-02 Orum Therapeutics, Inc. Anti-cd123 antibodies and neodegrader conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2358697E (pt) * 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
BR112022019532A2 (pt) * 2020-03-31 2022-12-06 Orum Therapeutics Inc Conjugados de neodegrader

Also Published As

Publication number Publication date
MX2023014284A (es) 2024-02-27
EP4346909A1 (en) 2024-04-10
AU2022287316A1 (en) 2023-12-14
TW202313124A (zh) 2023-04-01
PE20250115A1 (es) 2025-01-16
AU2022287316A9 (en) 2024-01-04
IL308811A (en) 2024-01-01
EP4346909A4 (en) 2026-05-06
CN119499399A (zh) 2025-02-25
KR20240040067A (ko) 2024-03-27
CA3222182A1 (en) 2022-12-08
CN118055779A (zh) 2024-05-17
US20250090681A1 (en) 2025-03-20
JP2024521921A (ja) 2024-06-04
CO2023016711A2 (es) 2024-02-26
WO2022254376A1 (en) 2022-12-08
CL2026000398A1 (es) 2026-03-20

Similar Documents

Publication Publication Date Title
CO2023016711A2 (es) Conjugados de neodegradadores
MX2022011825A (es) Conjugados neodegradadores.
CL2026000399A1 (es) Conjugados de neodegradador-anticuerpo anti-cd33.
CL2023001800A1 (es) Conjugados anticuerpo-fármaco específicos para tumores con claudina 18.2
DOP2025000112A (es) Compuestos moduladores de glp-1r
CU20210096A7 (es) Moléculas de unión a cd19
MX2024014691A (es) Enlazadores de conjugacion mejorados
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
CL2024001874A1 (es) Inhibidores de parp1.
MX2009008222A (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
CL2024002658A1 (es) Moléculas de unión contra fralfa
CL2021003039A1 (es) Moléculas de unión a tigit y pd-1/tigit
BR112023014128A2 (pt) Conjugados de anticorpo-fármaco imunomodulatórios
MX2020006010A (es) Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
CR20210180A (es) Moduladores de la expresión de pnpla3
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2024017273A2 (es) Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
MX2025000552A (es) Conjugados anticuerpo-fármaco
MX2021003136A (es) Conjugados de proteinas de union a toxinas que comprenden antraciclinas, y uso de los mismos en aplicaciones inmunooncologicas.
PE20200866A1 (es) Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso
MX2020010110A (es) Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
MX2025003990A (es) Conjugados neodegradadores
MX2022000283A (es) Peptidos mimetidos de bcl9 modificados.
MX2021007548A (es) Adc con enlazadores multiplex de tiol.